These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11677852)

  • 21. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy assessment in paediatric studies.
    Wang S; Laitinen-Parkkonen P
    Handb Exp Pharmacol; 2011; 205():149-68. PubMed ID: 21882110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development.
    Severino ME; Dubose RF; Patterson SD
    IDrugs; 2006 Dec; 9(12):849-53. PubMed ID: 17139572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 0 trials speed early drug development.
    McBride D
    ONS Connect; 2007 Sep; 22(9):21. PubMed ID: 17910234
    [No Abstract]   [Full Text] [Related]  

  • 28. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?
    Shah RR
    Pharmacol Ther; 2008 Aug; 119(2):215-21. PubMed ID: 18455801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective validation of genomic biomarkers-- what are the questions, challenges and strategies for developing useful relationships to clinical outcomes-- workshop summary.
    Wang SJ; Cohen N; Katz DA; Ruano G; Shaw PM; Spear B
    Pharmacogenomics J; 2006; 6(2):82-8. PubMed ID: 16402078
    [No Abstract]   [Full Text] [Related]  

  • 30. Toxicogenomics in predictive toxicology in drug development.
    Suter L; Babiss LE; Wheeldon EB
    Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surrogate markers in clinical studies: problems solved or created?
    Manns B; Owen WF; Winkelmayer WC; Devereaux PJ; Tonelli M
    Am J Kidney Dis; 2006 Jul; 48(1):159-66. PubMed ID: 16797400
    [No Abstract]   [Full Text] [Related]  

  • 32. Analgesia and anesthesia for neonates: study design and ethical issues.
    Anand KJ; Aranda JV; Berde CB; Buckman S; Capparelli EV; Carlo WA; Hummel P; Lantos J; Johnston CC; Lehr VT; Lynn AM; Maxwell LG; Oberlander TF; Raju TN; Soriano SG; Taddio A; Walco GA
    Clin Ther; 2005 Jun; 27(6):814-43. PubMed ID: 16117988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of biomarkers for risk stratification of cardiovascular events using genetic algorithm with recursive local floating search.
    Zhou X; Wang H; Wang J; Wang Y; Hoehn G; Azok J; Brennan ML; Hazen SL; Li K; Chang SF; Wong ST
    Proteomics; 2009 Apr; 9(8):2286-94. PubMed ID: 19337989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug testing. Regulators talk up plans for drug biomarkers ..
    Couzin J
    Science; 2004 Nov; 306(5699):1119. PubMed ID: 15539576
    [No Abstract]   [Full Text] [Related]  

  • 36. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging applications of kinetic biomarkers in preclinical and clinical drug development.
    Turner SM; Hellerstein MK
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):115-26. PubMed ID: 15679179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological biomarkers in psoriatic disease. A review.
    de Vlam K; Gottlieb AB; Fitzgerald O
    J Rheumatol; 2008 Jul; 35(7):1443-8. PubMed ID: 18609742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.